OTCPK:FNCHQ Key Ratios
| Market Cap $ M | 16.62 |
| Enterprise Value $ M | 16.62 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | -- |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -8.82 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.84 |
| EV-to-EBITDA | -0.85 |
| PEG | -- |
| Shares Outstanding M | 1.61 |
| Net Margin (%) | -- |
| Operating Margin % | -- |
| Pre-tax Margin (%) | -- |
| Quick Ratio | -- |
| Current Ratio | -- |
| ROA % (ttm) | -- |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -- |
| Dividend Yield % | -- |
| Altman Z-Score | -- |
FNCHQ Number of Guru Trades
FNCHQ Volume of Guru Trades
Gurus Latest Trades with OTCPK:FNCHQ
OTCPK:FNCHQ is held by these investors
Finch Therapeutics Group Inc Insider Transactions
Guru Commentaries on OTCPK:FNCHQ
Finch Therapeutics decided to move forward with a strategic Chapter 11 bankruptcy filing to sell the company. The trial court ruling resulted in a disappointing judgement for damages of $25.8 million, with a royalty rate of 5.5%. The final sale value was $32 million, which was below expectations. Despite this, the investment was deemed worth making due to downside protection and the potential for a higher return. However, the time taken to get a court ruling was underestimated, leading to a disappointing outcome overall.
Finch Therapeutics is currently pursuing a strategic Chapter 11 filing to eliminate lease obligations and facilitate the sale of the company. This includes valuable assets such as a litigation claim against Ferring Pharmaceuticals, which could yield between $25 and $80 per share, and 160 issued patents. The company has received healthy interest from potential buyers, and the manager believes this process will maximize shareholder value more effectively than remaining publicly traded. A resolution is expected in early June, and the manager anticipates a healthy premium over the purchase price.
Finch Therapeutics has shown significant potential following a favorable jury trial outcome against Ferring Pharmaceuticals, which awarded Finch approximately $30 million and ongoing royalties. The jury's finding of willful infringement opens the door for enhanced damages, potentially tripling the award. The manager believes that even in a worst-case scenario, Finch shares are worth at least double their current price, indicating strong upside potential. The situation is deemed worth waiting for, reflecting confidence in Finch's future prospects.
News about OTCPK:FNCHQ
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
